Dendritcellebaserede cancervacciner--klinisk anvendelse.

Inge Marie Svane; Annika Berntsen; Redas Trepiakas; Anders Elm Pedersen

Dendritcellebaserede cancervacciner--klinisk anvendelse.

Translated title of the contribution: Dendrite cell-based cancer vaccines--clinical application

Inge Marie Svane, Annika Berntsen, Redas Trepiakas, Anders Elm Pedersen

Department of Immunology and Microbiology

4 Citations (Scopus)

Abstract

Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach.
Udgivelsesdato: 2006-Apr-3

Translated title of the contribution	Dendrite cell-based cancer vaccines--clinical application
Original language	Danish
Journal	Ugeskrift for læger
Volume	168
Issue number	14
Pages (from-to)	1415-20
Number of pages	5
ISSN	0041-5782
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ab3a6340ac0411ddb5e9000ea68e967b,

title = "Dendritcellebaserede cancervacciner--klinisk anvendelse.",

abstract = "Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3",

author = "Svane, {Inge Marie} and Annika Berntsen and Redas Trepiakas and Pedersen, {Anders Elm}",

note = "Keywords: Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Female; Humans; Lymphocyte Activation; Male; Neoplasms; T-Lymphocytes; Treatment Outcome",

year = "2006",

language = "Dansk",

volume = "168",

pages = "1415--20",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "14",

}

TY - JOUR

T1 - Dendritcellebaserede cancervacciner--klinisk anvendelse.

AU - Svane, Inge Marie

AU - Berntsen, Annika

AU - Trepiakas, Redas

AU - Pedersen, Anders Elm

N1 - Keywords: Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Female; Humans; Lymphocyte Activation; Male; Neoplasms; T-Lymphocytes; Treatment Outcome

PY - 2006

Y1 - 2006

N2 - Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3

AB - Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach. Udgivelsesdato: 2006-Apr-3

M3 - Tidsskriftartikel

C2 - 16584668

SN - 0041-5782

VL - 168

SP - 1415

EP - 1420

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 14

ER -